Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi. Under the terms of the agreement, subject to customary conditions, Vicebio shareholders will receive up to a total of $1.6 billion, including an upfront payment of $1.15 billion as well as development and regulatory milestones payments of $450 million. Vicebio was created by Medicxi to develop next...